BofA raised the firm’s price target on Harmony Biosciences (HRMY) to $32 from $31 and keeps an Underperform rating on the shares after the company reported Q3 results after having pre-announced last week. The firm notes that its revised sales forecast reflects a slightly higher near-term launch ramp and FY25 mid-point guidance increase of 2%, adding that it raised Wakix forecasts 2%-3% in 2025-27.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences reports Q3 EPS $1.08, consensus 86c
- Harmony Biosciences backs FY25 revenue view $845M-$865M, consensus $860.5M
- Is HRMY a Buy, Before Earnings?
- Harmony Biosciences price target raised to $36 from $35 at Mizuho
- Harmony Biosciences Holdings: Strong Financial Performance and Promising Pipeline Drive Buy Rating